Chemotherapy Induced Peripheral Neuropathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chemotherapy Induced Peripheral Neuropathy pipeline constitutes 4+ key companies continuously working towards developing 5+ Chemotherapy Induced Peripheral Neuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chemotherapy Induced Peripheral Neuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Chemotherapy Induced Peripheral Neuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chemotherapy Induced Peripheral Neuropathy Market.

Some of the key takeaways from the Chemotherapy Induced Peripheral Neuropathy Pipeline Report: https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chemotherapy Induced Peripheral Neuropathy treatment therapies with a considerable amount of success over the years.
• Chemotherapy Induced Peripheral Neuropathy companies working in the treatment market are Wex Pharmaceuticals, Esteve, Algo Therapeutix, WinSanTor, Inc, Hoffmann-La Roche, Neo Therapeutics, NEMA Research, Inc., Boryung Pharmaceutical, and others, are developing therapies for the Chemotherapy Induced Peripheral Neuropathy treatment
• Emerging Chemotherapy Induced Peripheral Neuropathy therapies in the different phases of clinical trials are- HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxin, leteprinim potassium (Neotrofin), CesametTM (nabilone), sodium selenite pentahydrate, and others are expected to have a significant impact on the Chemotherapy Induced Peripheral Neuropathy market in the coming years.
• In March 2025, Dogwood Therapeutics, Inc. announced in a press release that the first patient has been dosed in the Phase 2b HALT-CINP (Halneuron® Treatment of Chemotherapy-Induced Neuropathic Pain) trial, which is evaluating Halneuron, a first-in-class therapy for neuropathic pain resulting from previous chemotherapy treatment.
• In February 2025, AlgoTherapeutix (AlgoTx), a clinical-stage biotechnology company developing ATX01, a first-in-class therapy for peripheral neuropathic pain, announced the completion of its 276-patient Phase 2 trial, named 'ACT' (ATX01 in ChemoTherapy-Induced Peripheral Neuropathy). Led by Professor Guido Cavaletti of the University of Milano-Bicocca, Italy, the ACT study is an international, double-blind, placebo-controlled trial assessing the efficacy and safety of two ATX01 concentrations in patients with CIPN, a common complication of neurotoxic cancer treatments caused by nerve degeneration.
• In October 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, has announced a licensing agreement with Alkem Laboratories Limited. This agreement grants Alkem rights for the research, development, manufacturing, marketing, and commercialization of SON-080 in India for treating diabetic peripheral neuropathy (DPN). Additionally, Alkem will handle the manufacturing, marketing, and commercialization of SON-080 for chemotherapy-induced neuropathy (CIPN) and autonomic neuropathy in India. SON-080 operates through a shared mechanism of action across these three neuropathies.
• In July 2024, The US Food and Drug Administration (FDA) has approved Artelo Biosciences' investigational new drug (IND) application, paving the way for a Phase I trial of the company's fatty acid-binding protein (FABP) inhibitor. ART26.12, Artelo's leading candidate, is noted as the first selective FABP5 inhibitor to reach clinical trials. The Phase I single ascending dose study will assess the drug's effectiveness in treating chemotherapy-induced peripheral neuropathy.
• In May 2024, Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical firm dedicated to advancing a novel class of biologic therapy for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), has revealed plans to participate in the 2024 Biotechnology Innovation Organization (BIO) International Convention.
• In March 2024, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet" or the "Company"), listed on NASDAQ as SONN, a clinical-stage biopharmaceutical company specializing in targeted immunotherapeutic drugs, announced today that the initial Phase 1b/2a clinical trial of SON-080 has been granted clearance to progress to Phase 2 following review by the independent Data Safety Monitoring Board (DSMB). This trial, labeled SB211 and registered under NCT05435742, is currently underway at two locations in Australia, focusing on patients with persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN) using an innovative proprietary version of recombinant human Interleukin-6 (rhIL-6). The clearance was necessary to confirm the safety of this new formulation before advancing to Phase 2 of development. CIPN is a condition where various drugs can cause damage to peripheral nerves, leading to significant discomfort for patients, including persistent and potentially unbearable pain, which may hinder ongoing chemotherapy treatment.

Chemotherapy Induced Peripheral Neuropathy Overview
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common side effect of certain chemotherapy drugs that affects the nerves outside of the brain and spinal cord, known as peripheral nerves. It typically presents as a tingling or numbness sensation, often starting in the hands and feet and potentially spreading upwards to the arms and legs.

Get a Free Sample PDF Report to know more about Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chemotherapy Induced Peripheral Neuropathy Drugs Under Different Phases of Clinical Development Include:
• HALNEURON: Wex Pharmaceuticals
• E-52862 (MR309): Esteve
• ATX01: AlgoTherapeutix
• WST-057 Active: WinSanTor, Inc
• Olesoxime (TRO19622): Hoffmann-La Roche
• Tetrodotoxin: Wex Pharmaceuticals Inc.
• leteprinim potassium (Neotrofin): NeoTherapeutics
• CesametTM (nabilone): NEMA Research, Inc.
• sodium selenite pentahydrate: Boryung Pharmaceutical

Chemotherapy Induced Peripheral Neuropathy Route of Administration
Chemotherapy Induced Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Chemotherapy Induced Peripheral Neuropathy Molecule Type
Chemotherapy Induced Peripheral Neuropathy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Chemotherapy Induced Peripheral Neuropathy Pipeline Therapeutics Assessment
• Chemotherapy Induced Peripheral Neuropathy Assessment by Product Type
• Chemotherapy Induced Peripheral Neuropathy By Stage and Product Type
• Chemotherapy Induced Peripheral Neuropathy Assessment by Route of Administration
• Chemotherapy Induced Peripheral Neuropathy By Stage and Route of Administration
• Chemotherapy Induced Peripheral Neuropathy Assessment by Molecule Type
• Chemotherapy Induced Peripheral Neuropathy by Stage and Molecule Type

DelveInsight's Chemotherapy Induced Peripheral Neuropathy Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chemotherapy Induced Peripheral Neuropathy product details are provided in the report. Download the Chemotherapy Induced Peripheral Neuropathy pipeline report to learn more about the emerging Chemotherapy Induced Peripheral Neuropathy therapies
https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chemotherapy Induced Peripheral Neuropathy Therapeutics Market include:
Key companies developing therapies for Chemotherapy Induced Peripheral Neuropathy are - Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Aptinyx Inc, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma K.K., and others.

Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis:
The Chemotherapy Induced Peripheral Neuropathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Peripheral Neuropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Peripheral Neuropathy Treatment.
• Chemotherapy Induced Peripheral Neuropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chemotherapy Induced Peripheral Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Peripheral Neuropathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chemotherapy Induced Peripheral Neuropathy drugs and therapies
https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chemotherapy Induced Peripheral Neuropathy Pipeline Market Drivers
• Increasing prevalence of cancer, Demand for effective treatments, Advancements in research, Regulatory incentives, Aging population, are some of the important factors that are fueling the Chemotherapy Induced Peripheral Neuropathy Market.

Chemotherapy Induced Peripheral Neuropathy Pipeline Market Barriers
• However, Complex pathophysiology, Lack of predictive biomarkers, Toxicity concerns, Clinical trial design challenges, Competition with existing treatments, Reimbursement challenges and other factors are creating obstacles in the Chemotherapy Induced Peripheral Neuropathy Market growth.

Scope of Chemotherapy Induced Peripheral Neuropathy Pipeline Drug Insight
• Coverage: Global
• Key Chemotherapy Induced Peripheral Neuropathy Companies: Wex Pharmaceuticals, Esteve, Algo Therapeutix, WinSanTor, Inc, Hoffmann-La Roche, Neo Therapeutics, NEMA Research, Inc., Boryung Pharmaceutical, and others
• Key Chemotherapy Induced Peripheral Neuropathy Therapies: HALNEURON, E-52862 (MR309), ATX01, WST-057 Active, Olesoxime (TRO19622), Tetrodotoxin, leteprinim potassium (Neotrofin), CesametTM (nabilone), sodium selenite pentahydrate, and others
• Chemotherapy Induced Peripheral Neuropathy Therapeutic Assessment: Chemotherapy Induced Peripheral Neuropathy current marketed and Chemotherapy Induced Peripheral Neuropathy emerging therapies
• Chemotherapy Induced Peripheral Neuropathy Market Dynamics: Chemotherapy Induced Peripheral Neuropathy market drivers and Chemotherapy Induced Peripheral Neuropathy market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.